Literature DB >> 25408366

Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report.

Maria Sepúlveda1, Sara Llufriu, Yolanda Blanco, Nuria Solà-Valls, Delon La Puma, Joan Berenguer, Pablo Villoslada, Albert Saiz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25408366     DOI： 10.1007/s00415-014-7574-6

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  15 in total

1.  Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?

Authors:  T Lenhard; A Biller; W Mueller; I Metz; J Schönberger; B Wildemann
Journal:  Neurology       Date:  2010-08-31       Impact factor: 9.910

Review 2.  Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Authors:  David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

3.  Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.

Authors:  Maarten J Titulaer; Lindsey McCracken; Iñigo Gabilondo; Thaís Armangué; Carol Glaser; Takahiro Iizuka; Lawrence S Honig; Susanne M Benseler; Izumi Kawachi; Eugenia Martinez-Hernandez; Esther Aguilar; Núria Gresa-Arribas; Nicole Ryan-Florance; Abiguei Torrents; Albert Saiz; Myrna R Rosenfeld; Rita Balice-Gordon; Francesc Graus; Josep Dalmau
Journal:  Lancet Neurol       Date:  2013-01-03       Impact factor: 44.182

4.  Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study.

Authors:  G Borriello; L Prosperini; C Mancinelli; C Giannì; F Fubelli; C Pozzilli
Journal:  Eur J Neurol       Date:  2011-11-07       Impact factor: 6.089

5.  Fingolimod after natalizumab and the risk of short-term relapse.

Authors:  Vilija G Jokubaitis; Vivien Li; Tomas Kalincik; Guillermo Izquierdo; Suzanne Hodgkinson; Raed Alroughani; Jeannette Lechner-Scott; Alessandra Lugaresi; Pierre Duquette; Marc Girard; Michael Barnett; Francois Grand'Maison; Maria Trojano; Mark Slee; Giorgio Giuliani; Cameron Shaw; Cavit Boz; Daniele L A Spitaleri; Freek Verheul; Jodi Haartsen; Danny Liew; Helmut Butzkueven
Journal:  Neurology       Date:  2014-03-07       Impact factor: 9.910

Review 6.  Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.

Authors:  B K Kleinschmidt-DeMasters; Augusto Miravalle; Jeffrey Schowinsky; John Corboy; Timothy Vollmer
Journal:  J Neuropathol Exp Neurol       Date:  2012-07       Impact factor: 3.685

7.  De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

Authors:  Joachim Havla; Lisa Ann Gerdes; Ingrid Meinl; Markus Krumbholz; Hans Faber; Frank Weber; Hannah Luise Pellkofer; Reinhard Hohlfeld; Tania Kümpfel
Journal:  J Neurol       Date:  2011-03-23       Impact factor: 4.849

8.  Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.

Authors:  L Daelman; A Maitrot; A Maarouf; M P Chaunu; C Papeix; A Tourbah
Journal:  Mult Scler       Date:  2012-08-20       Impact factor: 6.312

9.  No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.

Authors:  M Capobianco; A di Sapio; M Malentacchi; S Malucchi; M Matta; F Sperli; A Bertolotto
Journal:  Eur J Neurol       Date:  2014-07-03       Impact factor: 6.089

10.  What to expect after natalizumab cessation in a real-life setting.

Authors:  S Salhofer-Polanyi; A Baumgartner; J Kraus; E Maida; M Schmied; F Leutmezer
Journal:  Acta Neurol Scand       Date:  2014-04-10       Impact factor: 3.209
View more
  1 in total

1.  Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases.

Authors:  Aigli G Vakrakou; Dimitrios Tzanetakos; Maria-Eleptheria Evangelopoulos; Theodore Argyrakos; John S Tzartos; Maria Anagnostouli; Elissavet Andreadou; Georgios Koutsis; Georgios Velonakis; Panagiotis Toulas; Elias Gialafos; Antonios Dimitrakopoulos; Erasmia Psimenou; Leonidas Stefanis; Constantinos Kilidireas
Journal:  Ther Adv Neurol Disord       Date:  2021-05-18       Impact factor: 6.570
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.